Web27 Apr 2024 · SNDX-5613 is a potent, selective, small molecule inhibitor of the menin-MLL binding interaction that is being developed for the treatment of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) and NPM1 mutant AML. Web28 Jun 2024 · SNDX-5613 is described as a highly selective oral menin inhibitor developed for MLLr acute leukemias, which includes acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and NPM1 -mutant AML. The agent was granted orphan drug status previously for the treatment of adult and pediatric patients with AML.

Syndax Announces Orphan Drug Designation Granted to SNDX …

WebThe Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study (ASH 2024) Differentiation syndrome, all grade 2, was reported in 11 pts (16%) and resolved with steroids and/or hydroxyurea. Web27 Apr 2024 · SNDX-5613 is a potent, selective, small molecule inhibitor of the menin-MLL binding interaction that is being developed for the treatment of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) and NPM1 mutant AML. farmer approved tractor meals

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo!

WebSNDX Complete Syndax Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Web30 Jun 2024 · The FDA has granted a fast track designation to SNDX-5613 for the treatment of adult and pediatric acute leukemias that harbor mixed-lineage leukemia … Web28 Jun 2024 · SNDX-5613 was granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of patients with AML, and Fast Track designation for the … free online life expectancy calculator